Vertex Pharmaceuticals (VRTX) reached a significant support level, and could be a good pick for investors from a technical perspective. Recently, VRTX broke through the 20-day moving average ...

Below is Validea's guru fundamental report for VERTEX PHARMACEUTICALS INCORPORATED (VRTX). Of the 22 guru strategies we follow, VRTX rates highest using our P/B Growth Investor model based on the ...

In a report released today, Joon Lee from Truist Financial maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report). The company’s shares closed yesterday at $472.80.

Vertex Pharmaceuticals Incorporated VRTX reported adjusted earnings of $4.38 per share for the third quarter of 2024, surpassing the Zacks Consensus Estimate of $4.13. In the year-ago quarter ...

In a report released today, Jay Olson from Oppenheimer maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report), with a price target of $540.00. The company’s shares closed ...

While there are several candidates to make the next stock split announcement, Vertex Pharmaceuticals (NASDAQ:VRTX) may just trump them all when it reports earnings on Nov. 4. Just because a stock ...

Good day. And welcome to the Vertex Pharmaceuticals Third Quarter 2024 Earnings Call. All participants will be in a listen-only mode. [Operator Instructions] After today’s presentation, there ...

Investors with a lot of money to spend have taken a bullish stance on Vertex Pharmaceuticals VRTX. And retail traders should know. We noticed this today when the trades showed up on publicly ...

Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) have appreciated more than 40% since I shifted my coverage to hold/neutral last year, and I am not surprised since the company executed ...